PCSK9 and chronic kidney disease: For example, research into African genetic ancestry has led to critical insights, including the link between APOL1 variants and chronic kidney disease [207], the identification of G6PD variants that refine diabetes diagnostics [208], and loss of function variants in PCSK9 that contribute to lower low-density lipoprotein cholesterol levels—this latter discovery has spurred the development of PCSK9 inhibitor drugs [209].